
Trevi Therapeutics TRVI
$ 13.31
-3.69%
Annual report 2025
added 03-17-2026
Trevi Therapeutics Total Current Liabilities 2011-2026 | TRVI
Annual Total Current Liabilities Trevi Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.75 M | 10.5 M | 5.82 M | 13.4 M | 12.7 M | 5.56 M | 5.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.4 M | 5.2 M | 8.99 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
534 M | $ 9.13 | -0.76 % | $ 591 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.59 M | $ 0.91 | 2.42 % | $ 6.69 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 15.52 | -2.39 % | $ 49.6 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.47 | 1.19 % | $ 3.72 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Fortress Biotech
FBIO
|
49.7 M | $ 2.24 | 0.9 % | $ 62.5 M | ||
|
Galectin Therapeutics
GALT
|
8.03 M | $ 2.26 | 0.22 % | $ 144 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Harmony Biosciences Holdings
HRMY
|
252 M | $ 31.01 | -0.13 % | $ 1.78 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
ImmuCell Corporation
ICCC
|
3.98 M | $ 8.44 | - | $ 76.2 M | ||
|
Incyte Corporation
INCY
|
1.52 B | $ 98.87 | -0.23 % | $ 19.3 B | ||
|
InMed Pharmaceuticals
INM
|
2 M | $ 0.71 | 1.28 % | $ 1.74 M | ||
|
INmune Bio
INMB
|
8.42 M | $ 1.35 | 1.5 % | $ 33.4 M | ||
|
Innoviva
INVA
|
49.7 M | $ 23.13 | 0.35 % | $ 1.56 B | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Jaguar Health
JAGX
|
40.7 M | $ 7.55 | -4.13 % | $ 17.6 M | ||
|
KalVista Pharmaceuticals
KALV
|
57.4 M | $ 26.67 | -0.02 % | $ 1.44 B | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
37.1 M | $ 223.98 | -0.39 % | $ 4.1 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.22 | 7.69 % | $ 5.3 M | ||
|
Liquidia Corporation
LQDA
|
136 M | $ 38.39 | 0.62 % | $ 3.3 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.08 | 0.74 % | $ 436 M |